RxDoctor Payments Data

Tarush Khurana, MD

Internal Medicine · Saint Louis, MONPI 1720615172

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 71 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$304
  • Lilly USA, LLC$143
  • Amgen$114
  • Novo Nordisk$99
  • AstraZeneca$92
  • E.r. Squibb & Sons, L.L.C.$69
  • plus $328 from 11 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,149 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$71,511
Medicare patients
138
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$153,572
OzempicSemaglutide88$98,603
JardianceEmpagliflozin48$67,696
MounjaroTirzepatide54$63,222
FarxigaDapagliflozin Propanediol53$56,369
TrulicityDulaglutide38$39,537
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$27,803
ArexvyRsvpref3 Antigen/As01e/Pf93$26,927
XareltoRivaroxaban18$22,498
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,034
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$16,906
EntrestoSacubitril/Valsartan12$16,818
Breo ElliptaFluticasone/Vilanterol29$12,423
MyrbetriqMirabegron15$10,818
XanaxAlprazolam12$10,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$304$157,890195 claims
Lilly USA, LLCMounjaro, Trulicity$143$102,75992 claims
Novo NordiskOzempic$99$98,60388 claims
GSKArexvy, Trelegy Ellipta, Breo Ellipta$37$56,384140 claims
AstraZenecaFarxiga$92$56,36953 claims
Johnson & JohnsonXarelto$39$22,49818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →